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Lipid and lipoprotein profile in HIV-infected patients treated
with Lopinavir/Ritonavir as a component of the first combination
antiretroviral therapy
Abstract
Abstract We characterized lipid and lipoprotein changes associated with a lopinavir/ritonavir-containing
regimen. We enrolled previously antiretroviral-naive patients participating in the Swiss HIV Cohort
Study. Fasting blood samples (baseline) were retrieved retrospectively from stored frozen plasma and
posttreatment (follow-up) samples were collected prospectively at two separate visits. Lipids and
lipoproteins were analyzed at a single reference laboratory. Sixty-five patients had two posttreatment
lipid profile measurements and nine had only one. Most of the measured lipids and lipoprotein plasma
concentrations increased on lopinavir/ritonavir-based treatment. The percentage of patients with
hypertriglyceridemia (TG >150 mg/dl) increased from 28/74 (38%) at baseline to 37/65 (57%) at the
second follow-up. We did not find any correlation between lopinavir plasma levels and the
concentration of triglycerides. There was weak evidence of an increase in small dense LDL-apoB during
the first year of treatment but not beyond 1 year (odds ratio 4.5, 90% CI 0.7 to 29 and 0.9, 90% CI 0.5 to
1.5, respectively). However, 69% of our patients still had undetectable small dense LDL-apoB levels
while on treatment. LDL-cholesterol increased by a mean of 17 mg/dl (90% CI -3 to 37) during the first
year of treatment, but mean values remained below the cut-off for therapeutic intervention. Despite an
increase in the majority of measured lipids and lipoproteins particularly in the first year after initiation,
we could not detect an obvious increase of cardiovascular risk resulting from the observed lipid changes.
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Abstract
We characterized lipid and lipoprotein changes associated with a lopinavir/ritonavir-containing regimen. We
enrolled previously antiretroviral-naive patients participating in the Swiss HIV Cohort Study. Fasting blood
samples (baseline) were retrieved retrospectively from stored frozen plasma and posttreatment (follow-up)
samples were collected prospectively at two separate visits. Lipids and lipoproteins were analyzed at a single
reference laboratory. Sixty-five patients had two posttreatment lipid profile measurements and nine had only one.
Most of the measured lipids and lipoprotein plasma concentrations increased on lopinavir/ritonavir-based
treatment. The percentage of patients with hypertriglyceridemia (TG >150mg/dl) increased from 28/74 (38%) at
baseline to 37/65 (57%) at the second follow-up. We did not find any correlation between lopinavir plasma levels
and the concentration of triglycerides. There was weak evidence of an increase in small dense LDL-apoB during
the first year of treatment but not beyond 1 year (odds ratio 4.5, 90% CI 0.7 to 29 and 0.9, 90% CI 0.5 to 1.5,
respectively). However, 69% of our patients still had undetectable small dense LDL-apoB levels while on treat-
ment. LDL-cholesterol increased by a mean of 17mg/dl (90% CI 3 to 37) during the first year of treatment, but
mean values remained below the cut-off for therapeutic intervention. Despite an increase in the majority of
measured lipids and lipoproteins particularly in the first year after initiation, we could not detect an obvious
increase of cardiovascular risk resulting from the observed lipid changes.
Introduction
Lopinavir/ritonavir (LPV/r) is a boosted protease in-hibitor (PI) widely used at each stage of HIV disease due
to its antiviral activity, very low selection rate of resistant
mutants, and good tolerance.1 However, several studies have
shown a significant increase in triglycerides (TG) and total
cholesterol (TC) on LPV/r-based therapy.2–5 In general, com-
bination antiretroviral treatments (cART), in particular PI-
containing regimens, are thought to be involved in the genesis
of lipid abnormalities, especially hypertriglyceridemia.6–8 Yet
it is not clear whether changes in lipids and lipoproteins
are a direct effect of cART or the result of a more complex
scenario also involving genetic, virologic, immunologic, and
inflammatory factors.9–11 Independent from their origin,
lipid changes have led to concern about increased cardio-
vascular risk in HIV-infected patients.12–14 In addition towell-
established coronary heart disease (CHD) lipid risk factors,
such as increased low-density lipoprotein (LDL) and reduced
high-density lipoprotein (HDL), the U.S. National Cholesterol
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Education Program (NCEP) states that certain hypertrigly-
ceridemic lipid disorders are strong risk factors for CHD. In
particular, slightly triglyceride-enriched very-low-density li-
poprotein (VLDL) and small dense LDL-apolipoprotein B-100
(sdLDL-apoB) are regarded as emerging CHD lipid risk fac-
tors associated with hypertriglyceridemia.15
Most previous studies of lipid abnormalities in patients
treated with a LPV/r-based cART have some limitations: ei-
ther cART-experienced patients were also recruited,4,16–21
measurements were made irrespective of fasting status,2 or
not all relevant lipid and lipoproteins were measured.3,22–24
The aim of our study was a detailed assessment of lipids
and lipoproteins in fasting cART-naive patients before and
twice during an LPV/r-based therapy. In particular, we in-
vestigated risk factors associated with development of hy-
pertriglyceridemia and the possible association between TG
and slightly triglyceride-enriched VLDL, sdLDL, and LPV
plasma levels.
Materials and Methods
Study design and population
The Swiss HIV Cohort Study (SHCS) is a prospective
multicentric cohort study that enrolledmore than 15,600 HIV-
infected persons aged 16 years or older at seven outpatient
clinics or specialized private practices (http://www.shcs.ch).
Each SHCS patient undergoes a clinical visit every 6 months
with collection of clinical data and storage of plasma and cells.
In our study we included all the white SHCS patients, pre-
viously antiretroviral naive, who started an LPV/r-based
cART between March 2001 and January 2006. Only patients
in a fasting state (defined as 8 h without caloric intake)
were included in the study. Patients were taking LPV/r at
the standard daily dose (800/200mg) together with two or
three nucleoside reverse transcriptase inhibitors (NRTIs) for
more than 3 months. The exclusion criteria were previous
antiretroviral therapy, use of lipid-lowering drugs, TG
>500mg/dl, and no familial combined hyperlipidemia. To
characterize the lipid and lipoprotein profile of patients we
collected blood samples before initiation of treatment (base-
line) and twice during an LPV/r-based therapy (follow-up 1
and 2). The baseline lipid profile was assessed retrospectively
using retrieved frozen plasma samples from the SHCS col-
lection, whereas follow-up samples were prospectively col-
lected at two consecutive SHCS visits.
Laboratory parameters
Citrate plasma was obtained by centrifugation of blood for
20min at 1500g and deep-frozen at 808C until analysis.
VLDL were separated by ultracentrifugation (Airfuge, Beck-
man Coulter, Krefeld, Germany) at a density of 1.006 g/ml
(4 h, 208C, 95,000 rpm) using an A-95 rotor with 820-mm
Ultra-Clear tubes. LDL-cholesterol (LDL-C) was determined
after removal of VLDL in the resulting infranatant by sub-
tracting HDL-cholesterol (HDL-C) from TC concentration.
TC, HDL-C, and TG in plasma and lipoprotein fractions were
determined with commercially available enzymatic assays
(Synchron CX5, Beckman Coulter, Krefeld, Germany), apoli-
poprotein B (apoB) and lipoprotein (a) [Lp(a)] by turbimetry
using the same equipment. The antibody against Lp(a) used
for the assay was purchased from Technoclone, Vienna,
Austria, and antibodies against apoB from Beckman Coulter,
Krefeld, Germany. sdLDL-apoB was determined after ultra-
centrifugation at a density >1.044 g/ml in the resulting in-
franatant. All procedures and methods were checked for their
compatibility with citrate plasma. The obtained values were
corrected according to the dilution of blood with sodium cit-
rate. All determinations were performed in a central labora-
tory. The presence of slightly triglyceride-enriched VLDLwas
detected by a VLDL-triglyceride/VLDL-apoB ratio between 6
and 8. A ratio below 6 defined normally composed VLDL,
while a ratio >8.0 defined triglyceride-rich VLDL. A concen-
tration >13.5mg/dl of sdLDL-apoB was regarded as abnor-
mally high, while the detection limit was 5.3mg/dl. Lipid and
lipoprotein values were defined according to the thresholds
established by the U.S. NCEP. CD4 T lymphocytes were
quantified by flow cytometry. The plasma HIV-1 RNA level
was measured by a PCR assay (Amplicor HIV monitor;
Roche Diagnostic System; limit of detection <50 copies/ml).
LPV concentrations were measured in plasma extracted be-
fore the morning dose (C through), using a validated high-
performance liquid chromatography (HPLC) method.
Statistical analysis
A paired t-test is appropriate if there is a constant differ-
ence between baseline and follow-up measurements on the
same patient. We fit models that assume that this difference
(between baseline and follow-up) was not constant but var-
ied with time on LPV/r. In our models, time on LPV/r was
represented by a linear spline25 and this allows us to estimate
the rate of change (per year) during the first year after starting
and beyond 1 year. We give 90% confidence intervals for
these estimates in order to focus on the clinical implications of
the range of values in the interval.26 Because most patients
contributed two sets of data to each model (most have two
follow-up measurements), we estimated intervals using
robust standard errors calculated using generalized estimat-
ing equations (and assuming an independent working cor-
relation27). We also adjusted estimates for a set of prespecified
covariates (gender, smoking status, and baseline age, BMI,
CD4 counts per 100, and log10 viral RNA) in order to estimate
the rate of change for a ‘‘reference patient’’—a male smoker
with other covariates set at typical values (40 years, 25 kg/m2,
200 cells/ml, 5 log10 copies/ml; see Table 1).
For most lipid parameters, the outcome was the difference
between baseline and follow-up measurements with models
fit by linear regression. However, for two parameters, models
were fit using logistic regression. For sdLDL-apoB, more than
half of the values were below the limit of detection; therefore
the response for this parameter was whether the follow-up
measurement was known to be higher than at baseline. For
the ratio of VLDL-TG to VLDL-apoB, the response was
whether the follow-up measurement was more atherogenic
than at baseline, with the absolute difference between the
observed ratio and 7.0 used as a measure of atherogenic risk.
We also tested a limited number of prespecified hypotheses
about associations between increases in TG and changes in
other parameters. These were tested by replacing time on
LPV/r in our models with the level of another parameter
and we illustrate these associations using graphs. We used
Intercooled Stata Version 9.2 for analyses and R 2.5.1 for
graphics.
526 MAGENTA ET AL.
Results
Population and treatment outcome
We identified 84 patients initiating an LPV/r-based ther-
apy. Ten of these patients were excluded due to previous use
of NRTIs or NNRTIs. Sixty-five (88%) patients had their lipid
profiles measured prospectively at two consecutive SHCS
visits, while nine (12%) had only one follow-up measurement
(due to a change of antiretroviral therapy). The median time
between start of LPV/r and the first follow-up was 15 months
(range 1–51 months), while the median time between the first
and the second follow-up was 6 months (range 1–13 months),
resulting in a median time between start of LPV/r and the
second follow-up of 22 months (range 5–58 months). Baseline
characteristics of patients are shown in Table 1.
LPV/r-based therapy led to a reduction of median viral
load from 5.1 (range 1.7–7.8) to 1.7 (range 1.7–3.3) log10
copies/ml at follow-up 1 and 2. Of note, 66 (89%) patients at
follow-up 1 and 62 (95%) at follow-up 2 had an undetectable
HIV-1 RNA (<50 copies/ml). Meanwhile, median CD4 cell
count increased from 179 (range 2–675) at baseline to 363
(range 51–915) and 411 (range 32–827) at follow-up 1 and 2,
respectively (Table 2).
Lipids and lipoproteins
Lipid and lipoprotein values before and changes after the
initiation of an LPV/r-based cART are summarized in Table 3.
At baseline the mean values of TC, HDL-C, LDL-C, and TG
were 113 (SD 30) mg/dl, 28 (SD 8) mg/dl, 61 (SD 21) mg/dl,
and 141 (SD 74) mg/dl, respectively. LDL-C 130mg/dl (a
threshold regarded as significantly atherogenic according to
U.S. NCEP guidelines) was present in 1/74 patients (1%). Low
HDL-C levels (<40mg/dl) were found in 69/74 patients
(93%). Moreover, 28/74 patients (38%) had TG >150mg/dl.
Atherogenic slightly triglyceride-enriched VLDLs (defined
by a VLDL-TG to VLDL-apoB ratio between 6 and 8) were
present in 13/74 patients (18%). sdLDL-apoB values were
below the detection limit in 66/74 patients (89%) and 1/74
patients (1%) had elevated concentrations (>13.5mg/dl).
Elevated levels of Lp(a) (>30mg/dl) were present in 11/74
patients (15%).
After initiation of LPV/r-based cART, TG had a mean in-
crease of 110mg/dl (90% CI 15–210) during the first year
of treatment followed by little change beyond 1 year of
treatment (a decrease of 7mg/dl, 90% CI 42 to 28, Fig. 1A).
The percentage of patients with hypertriglyceridemia (TG
>150mg/dl) increased from 28/74 (38%) at baseline to 38/74
(51%) and 37/65 (57%) at follow-up 1 and 2, respectively. We
also tested a prespecified hypothesis that hypertriglycer-
idemia on treatment represents a worsening of a preexisting
condition by adding an interaction term to ourmodel between
TG at baseline and time on treatment. This interaction term
was estimated to be negative implying that higher baseline
values of TG show smaller increases over time than lower
baseline values of TG (Fig. 1B). Moreover, we found a small
decrease in TG for patients with higher HDL-C levels
(5.5mg/dl in TG, 90% CI 8.8 to 2.1, for each mg/dl in-
crease in HDL-C, see also Fig. 2A). There was no obvious
increase in the atherogenicity of the VLDL-TG to VLDL-apoB
ratio in either the first or subsequent years (odds ratio 0.6, 90%
CI 0.2 to 2.6, and 1.1, 90% CI 0.7 to 1.8, respectively). Con-
sistent with these estimates, the percentage of patients with an
atherogenic ratio of VLDL-TG to VLDL-apoB was relatively
constant with 13/74 (18%) patients at baseline and 14/74
(19%) and 13/65 (20%) patients at follow-up 1 and 2, re-
spectively. Moreover, we observed a roughly linear relation-
ship between the TG and VLDL-TG/VLDL-apoB ratio
(Fig. 2B).
The apoCII to apoCIII ratio declined by a mean 0.22 (90%
CI 0.39 to 0.05) during the first year of treatment and re-
mained stable thereafter. The decline of this ratio was driven
by a sizable increase in apoCIII during the first year of treat-
ment (7.5mg/dl, 90% CI 4.1 to 11). There was weak evidence
of a small decrease in TG for patients with higher apoCII to
Table 1. Baseline Characteristics
of 74 Antiretroviral-Naive Patients
Initiating an LPV/r-Based cART
Characteristic n (%)
Age [mean (SD)] 40 (10)
Male gender 65 (88%)
Route of HIV transmission
Intravenous drug user 11 (15%)
Homosexual 31 (42%)
Heterosexual 29 (39%)
Other 3 (4%)
Baseline BMI (kg/m2) [mean (SD)] 23 (4)
Current or ex-smokers 48 (65%)
HCV coinfected 11 (15%)
Concurrent NRTI backbone
ABC/3TC 3 (4%)
AZT/3TC 60 (81%)
AZT/ABC/3TC 1 (1%)
DDI/D4T 1 (1%)
TNV/3TC 4 (5%)
TNV/AZT/3TC 1 (1%)
TNV/DDI 2 (3%)
TNV/ETC 2 (3%)
Nadir CD4þ; <200 cells/ml 50 (68%)
HIV-1 RNA (log10 copies/ml) [mean (SD)] 5.2 (0.82)
CD4þ (cells/ml) [median (range)] 179 (2–675)
Table 2. CD4þ Cell Count, HIV1-RNA, and Body Mass Index at Baseline
and After the Initiation of an LPV/r-Based cARTa
Variable Baseline (n¼ 74) Follow-up 1 (n¼ 74) Follow-up 2 (n¼ 65)
CD4þ cells 179 (2–675) 363 (51–915) 411 (32–827)
HIV-1 RNA (log10 copies/ml) 5.1 (1.7–7.8) 1.7 (1.7–3.3) 1.7 (1.7–3.3)
BMI (kg/m2) 22.4 (14.4–37.8) 24.0 (15.7–37.9) 24.2 (15.7–39.4)
aAll values are given as median and range.
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Table 3. Mean (SD) Lipid and Lipoprotein Levels at Baseline and Estimated Mean Change
Per Year (90% CI) After the Initiation of an LPV/r-Based cARTa,b
Mean change per year (90% CI)
Variable Baseline level mean (SD) During first year Beyond first year
HDL-cholesterol 28 (8) 6.7 (0.3, 13) 0.7 (2.9, 1.5)
Apolipoprotein A-I 94 (22) 24 (6, 42) 3.9 (1.2, 8.9)
Apolipoprotein A-II 22 (4) 3.0 (0.1, 5.8) 0.6 (0.2, 1.4)
Total cholesterol 113 (30) 45 (20, 71) 3.1 (10, 4.3)
LDL-cholesterol 61 (21) 17 (3, 37) 0.3 (5.1, 5.6)
LDL apolipoprotein B 37 (12) 12 (2, 23) 1.2 (1.7, 4.2)
Apolipoprotein B 50 (15) 17 (4.7, 29) 0.4 (3.2, 4.0)
Small dense LDL-apolipoprotein Bc 8/74 (11%) 4.5 (0.7, 29) 0.9 (0.5, 1.5)
Lipoprotein (a) 14 (21) 3.2 (5.7, 12) 0.7 (2.4, 1.0)
Triglycerides 141 (74) 110 (15, 210) 7 (42, 28)
VLDL-cholesterol 24 (9) 22 (10, 34) 2.7 (7.0, 1.6)
VLDL-triglycerides 75 (50) 110 (21, 190) 0 (33, 32)
VLDL apolipoprotein B 12 (5) 4.2 (0.7, 7.7) 1.6 (2.7, 0.5)
VLDL-triglycerides/VLDL-apoB ratiod 13/74 (18%) 0.6 (0.2, 2.6) 1.1 (0.7, 1.8)
Apolipoprotein CII 2.7 (0.8) 1.1 (0.1, 2.2) 0.1 (0.4, 0.2)
Apolipoprotein CIII 7 (3) 7.5 (4.1, 11) 0.2 (1.4, 1.0)
Apolipoprotein CII/CIII ratio 0.5 (0.4) 0.22 (0.39, 0.05) 0.03 (0.07, 0.01)
Glucose 86 (21) 3.5 (8.7, 16) 6.1 (1.1, 13)
aChange was modeled as two slopes, during the first year and beyond the first year, and estimates were adjusted for six covariates (gender,
smoking status, and baseline age, body mass index (BMI), CD4 counts per 100, and log10 HIV-1 RNA).
bAll values are mg/dl (except ratios and proportions).
cSince most patients were below the detection limit, we report the percentage of patients with a detectable level at baseline and adjusted
odds ratio for whether follow-up measurements were known to be higher than at baseline.
dHere we report the percentage of patients with an atherogenic VLDL-triglycerides/VLDL-apoB ratio at baseline and estimate the adjusted
odds ratio of having a more atherogenic ratio over time on treatment, with the absolute difference between the observed ratio and 7.0 used as
a measure of atherogenic risk.
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FIG. 1. Triglyceride levels over time for 74 patients treated with an LPV/r-containing regimen. (A) A nonparametric
average response curve (calculated using the default LOESS function in R 2.5.1) and individual response profiles for a
random sample of 19 (25%) patients. (B) Nonparametric average response curves for patients with baseline triglycerides
150mg/dl (þ,   ) and for patients with baseline triglycerides >150mg/dl (o , . . .).
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apoCIII ratios (25mg/dl, 90%CI62 to 12 change in TG per
unit change in the apoCII to apoCIII ratio; see also Fig. 2C).
There was weak evidence of an increase in sdLDL-apoB
during the first year of treatment but not beyond 1 year (odds
ratios 4.5, 90% CI 0.7 to 29, and 0.9, 90% CI 0.5 to 1.5). Con-
sistent with these estimates, 66/74 patients (89%) had a con-
centration of sdLDL-apoB below the detection limit at
baseline compared with 51/74 (69%) patients and 45/65
(69%) patients at follow-up 1 and 2, respectively. Accordingly,
few follow-up measurements (40/139) showed an increase in
the level of sdLDL-apoB; most of them (99/139) showed no
discernible change or a decrease. However, in patients with
detectable sdLDL-apoB at follow-up, we found a higher in-
crease in TG from baseline to follow-up compared to patients
with sdLDL-apoB below the detection limit at follow-up (by
144mg/dl 90% CI 83 to 205, see also Fig. 2D). Highly ath-
erogenic concentrations of sdLDL-apoB (>13.5mg/dl) were
found in 2/74 (3%) and 0/65 patients at follow-up 1 and 2,
respectively, compared to 1/74 (1%) at baseline.
TC had a mean increase of 45mg/dl (90% CI 20 to 71)
during the first year of treatment followed by little change
beyond 1 year of treatment (a mean decrease of 3.1mg/dl,
90% CI 10 to 4.3).
LDL-C had a mean increase of 17mg/dl (90% CI 3 to 37)
during the first year of treatment followed by little change
beyond 1 year of treatment (amean increase of 0.3mg/dl, 90%
CI 5.1 to 5.6). LDL-C 130mg/dl was found in 2/74 (3%)
and 1/65 patients (2%) at follow-up 1 and 2, respectively,
compared with 1/74 (1%) at baseline.
HDL-C had a mean increase of 6.7mg/dl (90% CI 0.3 to 13)
during the first year of treatment followed by little change
beyond 1 year of treatment (a mean decrease of 0.7mg/dl,
95% CI 2.9 to 1.5). The number of patients with HDL-C
>40mg/dl increased from 5/74 (7%) at baseline to 9/74 (12%)
and 7/65 (11%) at follow-up 1 and 2, respectively.
Lp(a) had a mean increase of 3.2mg/dl (95% CI5.7 to 12)
during the first year of treatment followed by little change
beyond 1 year of treatment (a mean decrease of 0.7mg/dl,
90% CI2.4 to 1.0). Elevated plasma levels of Lp(a) (>30mg/
dl) were found in 13/74 (18%) and 11/65 patients (17%) at
follow-up 1 and 2, respectively, compared to 11/74 patients
(15%) at baseline.
Lopinavir plasma level and triglycerides
During the study period nine patients had only one mea-
surement of LPV through plasma concentration, while 65 had
two. The mean through plasma concentrations of LPV were
5.9 (SD 3) mg/ml and 6.2 (SD 4) mg/ml at the first and the
second follow-up, respectively. We did not observe any ob-
vious increase in TG with increasing plasma levels of LPV
(0.1mg/dl increase in TG, 90% CI 7.7 to 7.9, Fig. 3).
Discussion
HIV infection has itself a profound impact on lipid and
lipoprotein metabolism that is further influenced by anti-
retroviral drugs. In a population of 74 previously treatment-
naive HIV-infected patients we found that most of the lipid
and lipoprotein plasma levels increased after initiation of an
LPV/r-based cART. When time on treatment was considered
most of these increases tended to occur during the first year of
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FIG. 2. Triglyceride versus other lipid levels for 74 patients on an LPV/r-containing regimen. (A–D) Nonparametric
average response curves are shown (calculated using the default LOESS function in R 2.5.1) and the two values per patient
are connected for each patient. (B) The atherogenic range of the VLDL triglyceride to VLDL apolipoprotein B ratio is
indicated by vertical lines (between 6 and 8).
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cART and reached a plateau in the following years, as in
previous reports.3,5,19
As expected in a fairly advanced and untreated HIV pop-
ulation,10,28 TGs were already elevated at baseline in more
than one-third of our patients, with a further increase of
the percentage of patients with hypertriglyceridemia (TG
>150mg/dl) at follow-up. Triglycerides markedly increased
only during the first year of an LPV/r-based cART. However,
higher baseline values of TG were followed by a lower in-
crease over time. In other words the odds of having elevated
triglycerides on LPV/r therapy was lower in those patients
who already had elevated triglycerides at baseline. This result
is in contrast with data from other publications,3–5,19 but is
consistent with the results of a previous SHCS study involv-
ing patients on a PI other than LPV/r.7
We could not confirm a correlation between increase in
TG and higher LPV plasma concentration as reported in
some,18,24,29 but not all studies.21,30
Hypertriglyceridemia is characterized either by a normal
number of large, triglyceride-rich VLDLs or an increased
number of small VLDLs that are relatively poor in TG and rich
in cholesterol (slightly triglyceride-enriched VLDL). The latter
particles carry a strongly increased risk of coronary heart
disease as shown in patients with familial combined hyper-
lipidemia. As one VLDL contains one molecule of apoB, the
ratio of VLDL-TG to VLDL-apoB can be used to determine
VLDL composition31–33 and to better estimate atherogenicity
in patients with hypertriglyceridemia. In this study, there
was no obvious increase in the atherogenicity of the VLDL-TG
to VLDL-apoB ratio in either the first or subsequent years of
treatment. The percentage of patients with atherogenic
slightly triglyceride-enriched VLDL did not change appre-
ciably after initiation of LPV/r-based cART. Moreover, we
found a positive correlation between the increase in TG and a
higher VLDL-TG to VLDL-apoB ratio. This suggests that in
HIV-positive patients treated with antiretroviral therapy
there is a predominance of large, triglyceride-rich VLDL,
similarly to the VLDL pattern seen in familial hypertri-
glyceridemia associated with a low cardiovascular risk.31
We observed an important increase in apoC3 concentra-
tion and a concomitant decrease of the apoC2 to apoC3 ratio
after the initiation of a LPV/r-based cART, in agreement
with previous studies.16,17,34 Since apoC2 stimulates the
catabolism of VLDL via lipoprotein lipase, while apoC3 in-
hibits this pathway, our data support the hypothesis of a
decreased activation of lipoprotein lipase as a key factor
in the observed increase of TG.16,17,35 Moreover, genetic
variants of apoC3 have been found to be associated with
extreme hypertriglyceridemia in patients treated with
ritonavir-boosted PIs, introducing genetic variability as an
additional factor in the pathogenesis of cART-associated
hypertriglyceridemia.11
sdLDL-apoB, an emerging atherogenetic risk factor,15 is
thought to mediate the cardiovascular risk of certain hyper-
triglyceridemias.36,37 Atherogenicity of sdLDL-apoB is due to
a great capacity to infiltrate the arterial wall, a reduced af-
finity for the LDL receptors, and an increased susceptibility to
ex vivo oxidation.38 Although most of our population had
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FIG. 3. Lopinavir plasma levels and triglyceride for 74 patients treated with an LPV/r-containing regimen. A nonpara-
metric average response curve is shown (calculated using the default LOESS function in R 2.5.1) and the two values per
patient are connected for each patient.
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undetectable values of sdLDL-apoB (below 5.3mg/dl) before
and after initiation of an LPV/r-based cART, patients with
detectable sdLDL-apoB had, on average, a higher increase in
TG from baseline to follow-up. Yet highly atherogenic con-
centrations of sdLDL-apoB were found only in a small pro-
portion of subjects before and after an LPV/r-based cART.39,40
Other studies reporting on elevated sdLDL-apoB before and
after starting a cART with LPV/r may be influenced by a
previous treatment, since they were conducted on patients
who switched to a new regimen because of virologic failure or
drug intolerance.16,17
Themajority of our study population had low TC and LDL-
C mean values before starting antiretroviral treatment. Al-
though both TC and LDL-C increased in the first year after the
initiation of LPV/r, the mean follow-up values remained far
below the recommended therapeutic goal for LDL-C accord-
ing to the U.S. NCEP guidelines. Moreover, after the initia-
tion of an LPV/r-based cART only <3% of our population
had LDL-C values regarded as significantly atherogenic
(130mg/dl).
We found a minimal increase of HDL-C in the first year
after initiation of an LPV/r-based cART. Nevertheless, the
percentage of patients with protective HDL-C values
(>40mg/dl) increased from 7% at baseline to 12% on cART.
Lp(a), another emerging atherogenetic risk factor,15 tended
to increase in the first year after the initiation of LPV/r.
However, the percentage of patients with elevated values
associated with premature development of atherosclerosis
(>30mg/dl) did not increase on LPV/r-based cART.
The well-characterized population of cART-naive HIV-
infected patients enabled us to obtain an extensive assessment
of lipids and lipoproteins before and after the initiation of an
LPV/r-based cART. Laboratory samples were collected in a
fasting status and analyzed in a single reference laboratory.
However, the size of our population was relatively small, al-
though larger than the majority of previous studies that have
reported on this topic. The different NRTIs used in combi-
nation with LPV/r could have influenced the lipid profile, as
it has been shown for zidovudine and stavudine.41 Finally,
the use of frozen plasma samples prevented standardization
of the intervals between baseline and follow-up assessment of
lipid and lipoproteins. However, our models allowed for
variation in the timing of assessments. Similarly, we were not
able to measure additional laboratory parameters, i.e., lipo-
protein lipase and hepatic lipase, that could have been valu-
able to clarify some of the pathogenic pathways.
In conclusion, the majority of the measured lipids and li-
poproteins were shown to increase on an LPV/r-based cART.
We could not demonstrate a significant change in the per-
centage of patients with atherogenic plasma levels of lipo-
proteins commonly associated with hypertriglyceridemia,
such as slightly triglyceride-enriched VLDL and sdLDL-apoB.
However, the risk of cardiovascular events in our population
remains a concern mainly due to the high percentage of pa-
tients with low HDL,42 frequent smoking,43 and inflamma-
tory factors associated with HIV infection.44
Acknowledgments
We thank all involved physicians, study nurses, and most
importantly participants of the SHCS. This study has been
financed in the framework of the Swiss HIV Cohort Study,
supported by the Swiss National Science Foundation, and by
an unrestricted grant from Abbott Laboratories.
The members of the Swiss HIV Cohort Study are Barth J,
Battegay M, Bernasconi E, Bo¨ni J, Bucher HC, Bu¨rgisser P,
Burton- Jeangros C, CalmyA, Cavassini M, Dubs R, Egger M,
Elzi L, Fehr J, Fischer M, FleppM, Francioli P (President of the
SHCS), Furrer H (Chairman of the Clinical and Laboratory
Committee), Fux CA, Gorgievski M, Gu¨nthard H (Chairman
of the Scientific Board), Hasse B, Hirsch HH, Hirschel B, Ho¨sli
I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H,
Ledergerger B, Marinetti G, Martinez de Tejada B, Mu¨ller N,
Nadal D, Pantalco G, Rauch A, Regenass S, Richenbach M
(Head of Data Center), Rudin C (Chairman of the Mother &
Child Substudy), Schmid P, Schultze D, Scho¨ni-Affolter F,
Schu¨pbach J, Speck R, Taffe´ P, Tolenti A, Trkola A, Vernazza
P, von Wyl V, Weber R, Yerly S.
Author Disclosure Statement
No competing financial interests exist.
References
1. Panel on Antiretroviral Guidelines for Adult and Adoles-
cents: Guidelines for the use of antiretroviral agents in HIV-
infected adults and adolescents. Department of Health and
Human Services. (Updated 3 November 2008.) Available
from http//www.aidsinfo.nih.gov/ContentFiles/Adultand
AdolescentGL.pdf.
2. Walmsley S, Bernstein B, King M, et al.: Lopinavir-ritonavir
versus nelfinavir for the initial treatment of HIV infection. N
Engl J Med 2002;346:2039–2046.
3. Montes ML, Pulido F, Barros C, et al.: Lipid disorders in an-
tiretroviral-naive patients treated with lopinavir/ritonavir-
based HAART: Frequency, characterization and risk factors.
J Antimicrob Chemother 2005;55:800–804.
4. Martinez E, Domingo P, Galindo MJ, et al.: Risk of metabolic
abnormalities in patients infected with HIV receiving anti-
retroviral therapy that contains lopinavir-ritonavir. Clin In-
fect Dis 2004;38:1017–1023.
5. Kaplan SS and Hicks CB: Safety and antiviral activity of
lopinavir/ritonavir-based therapy in human immunodefi-
ciency virus type 1 (HIV-1) infection. J Antimicrob Che-
mother 2005;56:273–6.
6. Fontas E, van Leth F, Sabin CA, et al.: Lipid profiles in HIV-
infected patients receiving combination antiretroviral therapy:
Are different antiretroviral drugs associated with different
lipid profiles? J Infect Dis 2004;189:1056–1074.
7. Periard D, Telenti A, Sudre P, et al.: Atherogenic dyslipide-
mia in HIV-infected individuals treated with protease in-
hibitors. The Swiss HIV Cohort Study. Circulation 1999;100:
700–705.
8. Young J, Weber R, Rickenbach M, et al.: Lipid profiles for
antiretroviral-naive patients starting PI- and NNRTI-based
therapy in the Swiss HIV cohort study. Antivir Ther 2005;10:
585–591.
9. Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, and
Grunfeld C: The hypertriglyceridemia of acquired immu-
nodeficiency syndrome is associated with an increased
prevalence of low density lipoprotein subclass pattern B.
J Clin Endocrinol Metab 1993;76:1423–1427.
10. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P,
and Feingold KR: Lipids, lipoproteins, triglyceride clearance,
and cytokines in human immunodeficiency virus infection
LIPOPROTEIN PROFILE ON LOPINAVIR/RITONAVIR 531
and the acquired immunodeficiency syndrome. J Clin En-
docrinol Metab 1992;74:1045–1052.
11. Tarr PE, Taffe P, Bleiber G, et al.: Modeling the influence of
APOC3, APOE, and TNF polymorphisms on the risk of
antiretroviral therapy-associated lipid disorders. J Infect Dis
2005;191:1419–1426.
12. Currier JS, Lundgren JD, Carr A, et al.: Epidemiological ev-
idence for cardiovascular disease in HIV-infected patients
and relationship to highly active antiretroviral therapy.
Circulation 2008;118:e29-e35.
13. Friis-Moller N, Reiss P, Sabin CA, et al.: Class of anti-
retroviral drugs and the risk of myocardial infarction. N
Engl J Med 2007;356:1723–1735.
14. Mary-Krause M, Cotte L, Simon A, Partisani M, and Cost-
agliola D: Increased risk of myocardial infarction with du-
ration of protease inhibitor therapy in HIV-infected men.
AIDS 2003;17:2479–2486.
15. Executive Summary of The Third Report of The National
Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cho-
lesterol in Adults (Adult Treatment Panel III). JAMA 2001;
285:2486–2497.
16. Badiou S, Merle De BC, Dupuy AM, Baillat V, Cristol
JP, and Reynes J: Decrease in LDL size in HIV-positive
adults before and after lopinavir/ritonavir-containing regi-
men: An index of atherogenicity? Atherosclerosis 2003;168:
107–113.
17. Badiou S, De Boever CM, Dupuy AM, Baillat V, Cristol JP,
and Reynes J: Small dense LDL and atherogenic lipid profile
in HIV-positive adults: Influence of lopinavir/ritonavir-
containing regimen. AIDS 2003;17:772–774.
18. Gutierrez F, Padilla S, Navarro A, et al.: Lopinavir plasma
concentrations and changes in lipid levels during salvage
therapy with lopinavir/ritonavir-containing regimens. J
Acquir Immune Defic Syndr 2003;33:594–600.
19. Lafeuillade A, Hittinger G, Philip G, Lambry V, Jolly P, and
Poggi C: Metabolic evaluation of HIV-infected patients re-
ceiving a regimen containing lopinavir/ritonavir (Kaletra).
HIV Clin Trials 2004;5:392–398.
20. Meynard JL, Lacombe K, Poirier JM, et al.: Sustained increase
of HDL cholesterol over a 72-week period in HIV-infected
patients exposed to an antiretroviral regimen including
lopinavir/ritonavir. J Int Assoc Physicians AIDS Care 2008;
7:311–316.
21. Torti C, Quiros-Roldan E, Regazzi-Bonora M, et al.: Lipid
abnormalities in HIV-infected patients are not correlated
with lopinavir plasma concentrations. J Acquir Immune
Defic Syndr 2004;35:324–326.
22. Antoniou T, Park-Wyllie L, and Boyle E: A comparison
of dyslipidemias associated with either lopinavir/ritonavir- or
indinavir/ritonavir-based antiretroviral therapy. J Acquir
Immune Defic Syndr 2004;37:1666–1667.
23. Galindo MJ, Verdejo J, Gonzalez-Munoz M, Ferrer A, and
Polo R: Metabolic changes in protease inhibitor-naive
patients treated for 1 year with lopinavir/ritonavir. J Acquir
Immune Defic Syndr 2008;48:628–629.
24. Valerio L, Fontas E, Pradier C, et al.: Lopinavir/ritonavir
combination and total/HDL cholesterol ratio. J Infect
2005;50:229–235.
25. Greenland S: Dose-response and trend analysis in epidemi-
ology: Alternatives to categorical analysis. Epidemiology
1995;6:356–365.
26. Sterne JA and Davey SG: Sifting the evidence-what’s wrong
with significance tests? BMJ 2001;322:226–231.
27. Pan W, Louis TA, and Connett JE: A note on marginal linear
regression with correlated response data. Am Stat 2000;54:
191–195.
28. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, and
Pierson RN: Hypertriglyceridemia in the acquired immu-
nodeficiency syndrome. Am J Med 1989;86:27–31.
29. Gonzalez de RD, Blanco F, Garcia-Benayas T, Jimenez-
Nacher I, Gonzalez-Lahoz J, and Soriano V: Correlation
between lopinavir plasma levels and lipid abnormalities in
patients taking lopinavir/ritonavir. AIDS Patient Care STDS
2003;17:443–445.
30. Leon A, Martinez E, Sarasa M, et al.: Impact of steady-state
lopinavir plasma levels on plasma lipids and body compo-
sition after 24 weeks of lopinavir/ritonavir-containing ther-
apy free of thymidine analogues. J Antimicrob Chemother
2007;60:824–830.
31. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, and
Richter WO: Differentiating hyperlipidaemia associated
with antiretroviral therapy. AIDS 2003;17:189–194.
32. Brunzell JD, Albers JJ, Chait A, Grundy SM, Groszek E, and
McDonald GB: Plasma lipoproteins in familial combined
hyperlipidemia and monogenic familial hypertriglycer-
idemia. J Lipid Res 1983;24:147–155.
33. van Barlingen HH, Kock LA, de Man FH, Erkelens DW, and
De Bruin TW: In vitro lipolysis of human VLDL: Effect of
different VLDL compositions in normolipidemia, familial
combined hyperlipidemia and familial hypertriglyceridemia.
Atherosclerosis 1996;121:75–84.
34. Bonnet E, Ruidavets JB, Tuech J, et al.: Apoprotein c-III
and E-containing lipoparticles are markedly increased in
HIV-infected patients treated with protease inhibitors:
Association with the development of lipodystrophy. J Clin
Endocrinol Metab 2001;86:296–302.
35. Baril L, Beucler I, Valantin MA, et al.: Low lipolytic enzyme
activity in patients with severe hypertriglyceridemia on
highly active antiretroviral therapy. AIDS 2001;15:415–47.
36. Ayyobi AF, McGladdery SH, McNeely MJ, Austin MA,
Motulsky AG, and Brunzell JD: Small, dense LDL and ele-
vated apolipoprotein B are the common characteristics for the
three major lipid phenotypes of familial combined hyperlip-
idemia. Arterioscler Thromb Vasc Biol 2003;23:1289–1294.
37. Georgieva AM, Van Greevenbroek MM, Krauss RM, et al.:
Subclasses of low-density lipoprotein and very low-density
lipoprotein in familial combined hyperlipidemia: Relation-
ship to multiple lipoprotein phenotype. Arterioscler Thromb
Vasc Biol 2004;24:744–749.
38. Chapman MJ, Guerin M, and Bruckert E: Atherogenic, dense
low-density lipoproteins. Pathophysiology and new thera-
peutic approaches. Eur Heart J 1998;19:A24–A30.
39. Riddler SA, Li X, Otvos J, et al.: Antiretroviral therapy is as-
sociated with an atherogenic lipoprotein phenotype among
HIV-1-infected men in the Multicenter AIDS Cohort Study.
J Acquir Immune Defic Syndr 2008;48:281–288.
40. Trein A, Schnaitmann E, and Richter WO: Lower prevalence
of small, dense low-density lipoprotein (sd-LDL) in hyper
triglyceridemic HIV-infected patients than in non-HIV-
infected subjects. 4th IAS Conference on HIV Pathogenesis,
Treatment and Prevention, 22–25 July 2007, Sydney, Aus-
tralia. Abstract TUPEB074.
41. Madruga JR, Cassetti I, Suleiman JM, et al.: The safety and
efficacy of switching stavudine to tenofovir df in combina-
tion with lamivudine and efavirenz in HIV-1-infected pa-
tients: Three-year follow-up after switching therapy. HIV
Clin Trials 2007;8:381–390.
532 MAGENTA ET AL.
42. Duprez DA, Kuller LH, Tracy R, et al.: Lipoprotein particle
subclasses, cardiovascular disease and HIV infection.
Atherosclerosis 2009;207:524–529.
43. Glass TR, Ungsedhapand C, Wolbers M, et al.: Prevalence of
risk factors for cardiovascular disease in HIV-infected pa-
tients over time: The Swiss HIV Cohort Study. HIV Med
2006;7:404–410.
44. El-Sadr WM, Lundgren JD, Neaton JD, et al.: CD4þ count-
guided interruption of antiretroviral treatment. N Engl J Med
2006;355:2283–2296.
Address correspondence to:
Enos Bernasconi
Servizio di Malattie Infettive
Ospedale Regionale di Lugano, sede Civico
Via Tesserete 46
6903 Lugano
Switzerland
E-mail: enos.bernasconi@eoc.ch
LIPOPROTEIN PROFILE ON LOPINAVIR/RITONAVIR 533

